This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abd-Allah, S. A. Articles by Perkin, R. M. Search for Related Content PubMed PubMed Citation Articles by Abd-Allah, S. A. Articles by Perkin, R. M. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Intravenous Immunoglobulin as Therapy for Pediatric Guillain-Barré Syndrome

Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA 92350

Paul W. Jansen, MD

Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA 92350

Stephen Ashwal, MD

Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA 92350

Ronald M. Perkin, MD

Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA 92350

Seven children with Guillain-Barré syndrome were treated with intravenous immunoglobulin. Median patient age was 5.8 years. A standard dosage of 0.4 g/kg/day for 5 days was administered. Clinical improvement occurred on average within 2.4 ± 1.3 days of beginning intravenous immunoglobulin. One child required mechanical ventilation for 7 days. Eight comparable children with Guillain-Barré syndrome at our institution in a prior study treated with plasmapheresis alone had similar clinical results. However, the need for admission to the pediatric intensive care unit and duration of pediatric intensive care unit stay were lower in the intravenous immunoglobulin treated group (P < .05). There were no complications with intravenous immunoglobulin therapy except for a brief episode of hypotension in one patient. Review of the literature identified 74 additional children with Guillain-Barré syndrome successfully receiving intravenous immunoglobulin therapy. We suggest intravenous immunoglobulin as initial therapy for pediatric Guillain-Barré syndrome, because it appears equally as effective as plasmapheresis and is associated with fewer complications. (J Child Neurol 1997;12:376-380).

Journal of Child Neurology, Vol. 12, No. 6, 376-380 (1997)
DOI: 10.1177/088307389701200607


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Sarnaik, U. Sethuraman, and E. Jones A 31/2-Year-Old Child with Bilateral Lower Extremity Pain of 3 Weeks Duration Clinical Pediatrics, May 1, 2009; 48(4): 440 - 443. [PDF]

				R. Korinthenberg, J. Schessl, J. Kirschner, and J. S. Monting Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial Pediatrics, July 1, 2005; 116(1): 8 - 14. [Abstract] [Full Text] [PDF]

				R.A.C. Hughes, E.F.M. Wijdicks, R. Barohn, E. Benson, D.R. Cornblath, A. F. Hahn, J.M. Meythaler, R.G. Miller, J.T. Sladky, and J.C. Stevens Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, September 23, 2003; 61(6): 736 - 740. [Abstract] [Full Text] [PDF]